Clinical Trials Directory

Trials / Completed

CompletedNCT00479518

Prognostic Value of Cardiac and Renal Markers in Ischemic Stroke and Transient Ischemic Attack

Prognostic Value of Cardiac and Renal Markers in the Acute Phase of Ischemic Stroke or Transient Ischemic Attack :Albuminuria-Brain Natriuretic Peptide-Cystatine C in Stroke

Status
Completed
Phase
Study type
Observational
Enrollment
159 (actual)
Sponsor
University Hospital, Tours · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients with stroke or transient ischemic attack (TIA) are at high risk of poor outcome, recurrence of cardiovascular events or vascular death.Until now, no reliable predictive biological marker could be identified in the acute phase of stroke.We hypothese that, in the acute phase of ischemic stroke or TIA, the increase of cardiac ( brain natriuretic peptide, BNP) or renal markers (albuminuria, cystatin C)might predict recurrence of cardiovascular events or vascular death. We want to assess which one of these markers has the best prognosis value , in a prospective study of 300 stroke patients followed during 3 years.

Detailed description

Patients with ischemic stroke or TIA will be included in the 48 hours following the onset of symptoms, in 3 university hospitals.For each patient will be collected * 1 blood sample for the BNP measure in pg/ml * 1 blood sample for the Cystatin C measure in mg/l * 2 urinary samples to measure the albumine/creatinine ratio, at inclusion and 5 days after the inclusion, and to study the variation of albuminuria in micrograms/min. The clinical follow-up will be organized during 3 years. The following events will be notified: poor outcome (defined with the Barthel and Rankin scores), recurrence of cardiovascular or cerebrovascular events, vascular death. After adjustment on the main clinical prognosis factors, we want to determine wich one of these markers has the best prognosis significance and allows to identify in the acute phase the "high-risk" patients, in order to intensify individual treatment and secondary prevention.

Conditions

Timeline

Start date
2007-03-01
Primary completion
2014-04-01
Completion
2017-02-01
First posted
2007-05-28
Last updated
2017-02-27

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00479518. Inclusion in this directory is not an endorsement.